
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2022

Commission File Number: 001-40277

OLINK HOLDING AB (PUBL)
(Exact Name of Registrant as Specified in its Charter)

Uppsala Science Park
SE-751 83
Uppsala, Sweden
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

As previously announced, on January 12, 2022, Jon Heimer, CEO of Olink Holding AB (publ) (the "Company"), made a presentation virtually at 9:00 am ET at the 40th Annual J.P. Morgan Healthcare Conference. An archived webcast of the event will be available on the "Events" section of the Company's website at <https://investors.olink.com/news-events/events>. A copy of the presentation is furnished as Exhibit 99.1 to this Form 6-K.

<u>Exhibit No.</u>	<u>Description</u>
---------------------------	---------------------------

<u>99.1</u>	<u>Olink Holding AB (publ) Presentation, 40th Annual J.P. Morgan Healthcare Conference, January 12, 2022.</u>
-----------------------------	---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

OLINK HOLDING AB (PUBL)

By: /s/ Jon Heimer

Name: Jon Heimer

Title: Chief Executive Officer

Date: January 12, 2022



Olink Proteomics

Vision
Enable understanding of real-time human biology

Mission
Accelerate proteomics together

JP Morgan 2022

January 12, 2022

Disclaimer


This presentation may contain certain forward-looking statements and opinions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained in this presentation include, but are not limited to, statements about: our addressable market, market growth, future revenue, key performance indicators, expenses, capital requirements and our needs for additional financing, our commercial launch plans, our strategic plans for our business and products, market acceptance of our products, our competitive position and developments and projections relating to our competitors, domestic and foreign regulatory approvals, third-party manufacturers and suppliers, our intellectual property, the potential effects of government regulation and local, regional and national and international economic conditions and events affecting our business. We cannot assure that the forward-looking statements in this presentation will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.

The forward-looking statements and opinions contained in this presentation are based on our management’s beliefs and assumptions and are based upon information currently available to our management as of the date of this presentation and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Actual results, performance or events may differ materially from those in such statements due to, without limitation, risks generally associated with product development, including delays or challenges that may arise in the development, launch or scaling of our new products, programs or services, challenges in the commercialization of our products and services, the risk that we may not maintain our existing relationships with suppliers or enter into new ones, or that we will not realize the intended benefits from such relationships, any inability to protect our intellectual property effectively, changes in general economic conditions, in particular economic conditions in the markets on which we operate, changes affecting interest rate levels, changes affecting currency exchange rates, changes in competition levels, and changes in laws and regulations, and other risks described under the caption “Risk Factors” in our Registration Statement on Form F-1 (File No. 333-257842) and other documents we file with the Securities and Exchange Commission from time to time. The information, opinions and forward-looking statements contained in this announcement speak only as of its date, and are subject to change without notice and we undertake no obligation to update any such forward-looking statements for any reason, except as required by law.

This presentation contains estimates, projections and other information concerning our industry, our business, and the markets for our products and services. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we believe our internal company research as to such matters is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source.



Uniquely addressed all challenges in proteomics – highest data quality



Sensitivity



Specificity



Dynamic range



Sample consumption



Throughput



Cost

Proven execution, delivering on all strategic levers in 2021



75-76%

Year on year revenue growth in FY21 (unaudited)

\$94.5-95.0

FY21 \$m revenues (unaudited)
Revenue guidance - \$90-92 for FY21

60%

Explore revenues as % of total revenues FY21

~35%

Q4 reagent kit share of revenues

~2x

Team expansion in 2021 to 416 employees


100%

Coverage of the plasma proteome using Explore 3072

56k UKBB

Samples delivered in H2 2021 to the UKBB consortia

Strong execution of externalizations with significant headroom to grow






Actionable science driving rapid customer adoption and growth

Evolution of publications based on PEA (as of December 2021)
Number of publications (accumulated)

Customer account acquisition
Total number of accounts served since inception






Olink
Accelerating proteomics together


Why scientists are using our products

Reducing risk in drug development, saving time and money







~\$35B TAM derived from Research (\$19bn) and Dx (\$16bn) markets
From high-plex to low-plex, Olink participates along the entire spectrum





Unique and holistic product offering applicable from Discovery to Dx



Explore NGS

Measure ~3k proteins with minimal biological sample. Aggressively expand our protein biomarker targets to meet every customer need across all proteomics use cases .

Explore 384 NGS

Minute sample volume, <1µl, and outstanding throughput, 14 M measurements per week/system

Explore kit launch in 2021

Target 96 qPCR

Choose from fifteen carefully designed panels built for specific area of disease or key biology process

Target 48 qPCR

Introducing our 48-plex Cytokine panel with absolute quantification

Aggressive expansion of product portfolio and offering

Signature qPCR

Light and nimble benchtop system purpose built for PEA. Opened up order books in Q2 for Q4 deliveries and revenue recognition

Focus qPCR

Forming the basis of our Dx offering

Custom developed for each client/use case

First LDT by Octave Bioscience to monitor disease management / progression in Multiple Sclerosis (MS). 2021 launch



Break-through science with Olink during 2021 in high-impact peer reviewed literature

The collage features several high-impact scientific articles:

- Nature**: "Large-scale plasma proteomic profiling identifies a high-performant biomarker panel for Alzheimer's disease screening and staging" by Hwang et al.
- Nature Medicine**: "Proteomics Enabled Deep Learning Machine Algorithms Can Enhance Prediction of Mortality" by Wang et al.
- Nature Medicine**: "Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions" by Wang et al.
- Nature Reviews Clinical Oncology**: "Genomic and drug target evaluation of 90 cardiovascular proteins in 30,531 individuals" by Leach et al.
- Nature Reviews Clinical Oncology**: "Plasma proteomics identifies tumour-inhibitory factor 8 and predictive biomarker of immune-checkpoint blockade via T cell activation" by Wang et al.
- Scientific Reports**: "Untargeted longitudinal analysis of a wellness cohort identifies markers of metastatic cancer years prior to diagnosis" by Wang et al.
- Scientific Reports**: "Systemic Inflammation in Preclinical Uterine Cells" by Wang et al.
- Scientific Reports**: "Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFpEF from the EMPEROR Study" by Wang et al.



Summary

Executive summary

- Superior disruptive proprietary technology
- Exceptional go-to market strategy
- Very strong commercial execution
- Transparent stable business model, easy to work with
- 75% - 76% YoY growth led by rapid expansion in high-plex
- >750 customers with a global footprint
- Market validation of reagent kit strategy – Explore, Target, and Focus
- 214 -> 416 FTEs in 2021 (150 in commercial team)

Looking ahead

- \$35B TAM
- Continued strong growth, aim for #1 market share in the emerging field of proteomics
- Establish NPX as the gold standard in proteomics
- Agnostic to NGS and qPCR platforms
- Library expansion: 4.5k to 6k and beyond
- Unlocking the mid-plex market with Signature and Flex Plex
- Continue to drive PEA in clinical decision making
- Continue to scale up the organization to accelerate growth



Olink
Accelerating proteomics together

Our vision

Enable
understanding of
real-time human
biology

Our mission

Accelerating
proteomics
together

Genomics

Epigenomics

Transcriptomics

Proteomics

Metabolomics

A complete picture of
real-time human biology